Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
1,366 people get AVEO articles and Market Currents by email alert.
Get email alerts on AVEO »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Biotech IPO: AVEO Pharma Develops Cancer TherapeuticsSA Editor Mohit Manghnani • Thu, Mar 11, 2010
-
at CNBC.com (Apr 26, 2013)
-
Business Wire (Jan 22, 2013)
-
Business Wire (Jan 17, 2013)
-
at CNBC.com (Nov 14, 2012)
-
at MarketWatch.com (Aug 2, 2012)
-
at MarketWatch.com (Aug 2, 2012)
-
Business Wire (May 3, 2012)
-
Business Wire (Apr 30, 2012)
-
Business Wire (Apr 26, 2012)
-
Business Wire (Apr 12, 2012)
-
Business Wire (Mar 27, 2012)
-
Business Wire (Jan 2, 2012)
-
Business Wire (Dec 28, 2011)
-
at MarketWatch.com (Jul 28, 2011)
-
at MarketWatch.com (Jun 15, 2011)
-
at MarketWatch.com (Jun 15, 2011)
-
at MarketWatch.com (Feb 17, 2011)
AVEO vs. ETF Alternatives
Company Description
Currently, there's no company description for AVEO.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
-
Wednesday, May 15, 9:14 AM
Premarket gainers: CHCI +41%. DVR +25%. CLNT +14%. VIPS +13%. EJ +11%. AFFY +9%. CHLN +9%. SPWR +8%. AVEO +5%.
Losers: XONE -10%. RMTI -8%. WMC -5%. 2 Comments [On the Move] - Friday, May 3, 9:54 AM Delcath Systems (DCTH -48.9%) collapses after the FDA votes unanimously against the company's Melblez Kit, as the risks purportedly outweigh the benefits. The shares were halted Thursday pending the announcement. DCTH is the second casualty of this week's Oncologic Drugs Advisory Board, as Aveo Pharmaceuticals (AVEO +1.5%) received a similarly disappointing panel vote on Tivozanib. (Background: I, II) Comment! [Healthcare, On the Move]
- Thursday, May 2, 1:27 PM Shares of Aveo Pharmaceutical (AVEO -48%) resume trading after being halted earlier in the day following an FDA panel vote of 13 to 1 that its application for Tivozanib did not demonstrate a favorable benefit-to-risk evaluation for the treatment of advanced renal cell carcinoma. Comment! [Healthcare, On the Move]
-
Tuesday, April 30, 12:46 PM
Midday top 10 gainers: TTHI +45%. PTIE +26%. DRRX +26%. MTOR +23%. MGAM +20%. OIS +16%. GIB +14%. HGSH +15%. ARWR +13%. TXRH +13%.
Midday top 10 losers: DCTH -44%. AVEO -26%. NUAN -18%. AOSL -18%. PBI -16%. AEIS -13%. MSTR -10%. ANV -10%. ELTK -10%. SYN -10%. Comment! [On the Move] -
Tuesday, April 30, 9:10 AM
Premarket gainers: HPY +10%. HTWR +9%. ANAD +9%. AVP +8%. UBS +7%. BBY +6%.
Losers: DCTH -20%. AVEO -16%. NUAN -15%. PBI -10%. MTG -8%. CNH -6%. RVBD -6%. QGEN -5%. Comment! [On the Move] - Tuesday, April 30, 9:01 AM Shares of Aveo Pharmaceuticals (AVEO) fall 17% premarket as the FDA asks the Oncologic Drugs Advisory Committee to help evaluate whether a single randomized trial is sufficient to warrant marketing approval for AVEO's renal cell carcinoma treatment tivozanib or whether further testing is necessary. Comment! [Healthcare, On the Move]
- Monday, April 29, 6:39 AM Aveo Pharmaceuticals (AVEO): Q1 EPS of -$0.69 beats by $0.03. Revenue of $300K. (PR) Comment! [Breaking News, Earnings, Healthcare]
-
Thursday, April 25, 9:12 AM
Premarket gainers: MPG +23%. INFN +19%. AKAM +17%. FIO +16%. CLF +8%. YNDX +7%. NXST +7%. NOW +7%. CAB +6%. CAKE +6%.
Losers: XIDE -15%. WHX -14%. INTU -13%. ZNGA -9%. MLNX -8%. AVEO -7%. CTXS -7%. 1 Comment [On the Move] -
Wednesday, April 3, 5:35 PM
After-hours top gainers, as of 5:15 p.m.: CCG +8%. ANV +5%. AVEO +4%. GFI +3%. VALE +2%.
After-hours top losers: SFUN -6%. IMUC -3%. CPWR -3%. LSE -3%. ROC -2%. Comment! [On the Move] - Wednesday, February 13, 9:29 AM AVEO Pharma (AVEO) -12.5% premarket even as its Q4 net loss narrowed from the year-ago quarter, primarily due to a milestone from Astellas recognized upon the acceptance of a new drug filing. But AVEO also announced disappointing results for its tivozanib drug from a Phase 3 TIVO-1 study in patients with advanced renal cell carcinoma. Comment! [Healthcare, Earnings, On the Move]
-
Wednesday, February 13, 9:10 AM
Premarket gainers: RCON +56%. PPHM +17%. EZCH +11%. WFR +9%. CMCSA +8%. GRPN +8%. VG +5%.
Losers: RATE -18%. CLF -14%. RAX -12%. AVEO -11%. AMX -6%. DF -6%. NICE -5%. Comment! [On the Move] - Wednesday, February 13, 6:37 AM AVEO Pharma (AVEO): Q4 EPS of -$0.49 beats by $0.16. Revenue of $15.5M beats by $1.01M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Wednesday, February 13, 12:05 AM Notable earnings before Wednesday’s open: ASPS, AVEO, CPN, DE, DF, DPS, DUK, EZCH, FBN, H, HSP, LO, PES, PRLB, TLM, TRI, VG, WCG, WFR 1 Comment [Earnings]
- Tuesday, February 12, 5:30 PM Notable earnings before Wednesday’s open: ASPS, AVEO, CPN, DE, DF, DPS, DUK, EZCH, FBN, H, HSP, LO, PES, PRLB, TLM, TRI, VG, WCG, WFR Comment! [Earnings]
-
Thursday, January 17, 9:10 AM
Premarket gainers: NEWL +64%. KSWS +48%. PATH +11%. CBS +9%. ROYL +8%. NUS +6%.
Losers: CLSN -10%. AVEO -5%. Comment! [On the Move] - Wednesday, January 16, 4:40 PM AVEO Pharmaceuticals (AVEO) announces a secondary offering for an undisclosed amount of shares. All of the shares in the offering are to be sold by AVEO, with JPMorgan acting as sole book-running manager and RBC Capital Markets and Canaccord as co-lead managers. Shares -1.5% AH. Comment! [Healthcare, On the Move]
-
Alp Bugra Basat
$Bottom fishers buy $AVEO, mentioned several days ago in my stock twitter @ http://bit.ly/10MGJjt - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
Scott Matusow
Check out what a Member of the upcoming $AVEO Adcomm has to say about RCC drugs with PFS improvement. http://bit.ly/14UYRi8 - View all 6 replies
-
-
-
- View all 0 replies
-
- View all 1 replies
-
Speedy12: My guess is other institutions added as well. Also recent strong insider buying. Wise to follow the "SMART" money.
-
- View all 0 replies
-
- View all 0 replies
-
Chris Rees
Why Chris Rees expects the FDA to approve Aveo's Tivozanib $AVEO $PFE $GSK $$ http://bit.ly/ZpkNJz - View all 0 replies
LATEST REPLIES
-
Scott Matusow
Check out what a Member of the upcoming $AVEO Adcomm has to say about RCC drugs with PFS improvement. http://bit.ly/14UYRi8 - View all 6 replies
-
-
-
- View all 1 replies
-
Speedy12: My guess is other institutions added as well. Also recent strong insider buying. Wise to follow the "SMART" money.
-
- View all 17 replies
-
-
-
Scott Matusow
Anyone want to bet me that $AVEO is over $7 by next week? any takers? Wed, 11:42 AM << they shorted, they lose - View all 6 replies
-
-
-
Scott Matusow
$LGND $19.05 alerted at $16.60 $BGMD $1.35 alerted at $1.05 $AVEO $6.80 alerted at $6.60 $FOLD $4.85 alerted at $4.35 - View all 4 replies
-
-
Scott Matusow: blak, u must lose money in the market -- I also gave a price target of $2.25 after financing -- that's on traders, now learn to make money
-
- View all 4 replies
-
-
-
- View all 1 replies
-
Noreika: Received your heads up yesterday. Another nice call I didn't play. I'm still all in VRNG waiting for something/anything. Have a good holiday
-
Scott Matusow
I bought more $AVEO I like this one after reading data, NDA should be accepted, 70 - 80% shot, way undervalued, plenty of cash on hand - View all 2 replies
-
Nahodny Okoloiduci: i don't like yesterdays AH action (at not much volume, though).. arent't you afraid of massive inst selling if it dips below $5? -
Scott Matusow: it was a misprint i watch af trading, it was a carry over trade from reg session 6.59. mis printed as 5.59
-
Scott Matusow
CORRECTION: Alert, I bought @$6.60 $AVEO as run-up ahead of FDA Decision on Tivozanib 11/28/12 - View all 4 replies
-
-